CMML Prognostic Scoring Systems (from Spain and Dusseldorf)
Assess risk of progression to AML and early mortality in CMML
CMML is a stem cell disorder with heterogeneous clinical and pathologic features, often sharing characteristics of both myelodysplastic and myeloproliferative disorders. This study of 235 individuals registered in a German MDS Registry determined prognostic findings associated with overall survival and transformation to acute myeloid leukemia, specific to CMML. The authors identified 4 factors that were able to differentiate patients into 3 risk categories with expectant median survivals ranging from 11 months to 93 months. An alternative scoring system (from the Spanish Registry) is an option when cytogenetic studies are available.
Such E, Cervera J, Nomdedeu B, Pedro C, Bueno J, et al.
A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology. New Orleans: Blood; 2009:abstract # 1750.
Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W.
Leukemia 1992, 6 (1): 52-9
The CMML Prognostic Scoring Systems (from Spain and Dusseldorf) calculator is created by QxMD.